Results 41 to 50 of about 2,108 (191)

Real‐world outcomes of aflibercept 8 mg in patients previously treated for neovascular age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.
Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem, Esra Inci, Martin Breimer, Sofia Töyrä Silfverswärd, Madeleine Zetterberg, Marita Andersson Grönlund   +5 more
wiley   +1 more source

Anti-vascular endothelial growth factor therapies in ophthalmology [PDF]

Background: Retinal diseases, including neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, are leading causes of vision loss worldwide.
Karti, Omer, Koksaldi, Seher, Saatci, Ali Osman   +2 more
core   +2 more sources

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials

Ophthalmology Science
Purpose: To compare the effect of faricimab, a dual angiopoietin-2 (Ang-2) and VEGF-A inhibitor, with aflibercept on resolution of hyperreflective foci (HRF) in patients with diabetic macular edema (DME).
Usha Chakravarthy, FRCOphth, PhD, Varun Chaudhary, MD, FRCS(C), Srinivas R. Sadda, MD, Colin S. Tan, FRCOphth, FRCSEd (Ophth), Stela Vujosevic, MD, PhD, Sascha Fauser, MD, Kara Gibson, PhD, Carl Glittenberg, MD, Nancy Holekamp, MD, FASRS, Ben Lanza, PhD, Andreas Maunz, PhD, Jeffrey R. Willis, MD, PhD, Rishi P. Singh, MD   +12 more
doaj   +1 more source

Faricimab in Neovascular AMD

, 2023
Abstract Purpose Assess short-term real-world outcomes in neovascular aged-related macular degeneration (nAMD) treated with novel faricimab. Methods Retrospective case series of nine patients with nAMD (11 eyes) treated with faricimab between May and November 2022.
Paulo Eduardo Stanga, Francisco Javier Valentin Bravo, Sebastian Stanga, Ursula Reinstein, Salvador Pastor Idoate, Susan Downes   +5 more
openaire   +1 more source

Faricimab in Neovascular AMD Complicated by Pigment Epithelium Detachment: An AI-Assisted Evaluation of Early Morphological Changes [PDF]

Introduction: This study investigates the early temporal changes in pigment epithelial detachment (PED) morphology following treatment with faricimab in patients with neovascular age-related macular degeneration (nAMD).
Gonfiantini M., Lanzetta P., Rubinato L., Sarao V., Veritti D.   +4 more
core   +1 more source

KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. [PDF]

, 2023
PURPOSE To report the 100-week outcomes from KESTREL and KITE. DESIGN Two phase 3, double-masked, active-controlled, randomized trials. METHODS Patients with diabetic macular edema (DME) were randomized 1:1:1 to brolucizumab 3 mg/6 mg ...
Agostini, Hansjuergen T, Bouillaud, Emmanuel, Brown, David M, Chang, Andrew, Dhoot, Dilsher S, Garweg, Justus G, Kovacic, Lidija, Laude, Augustinus, Regillo, Carl, Souied, Eric, Wachtlin, Joachim, Wang, Lixin, Wang, Ying, Wolf, Sebastian, Wykoff, Charles C   +14 more
core   +1 more source

Analysis of the aqueous humor before and after the administration of faricimab in patients with nAMD

Scientific Reports
This study aimed to evaluate the changes in cytokine levels in the aqueous humor and factors of treatment resistance following intravitreal faricimab injection in treatment-naïve patients with neovascular age-related macular degeneration.
Ryo Nonogaki, Hikaru Ota, Jun Takeuchi, Yuyako Nakano, Ai Fujita Sajiki, Takahito Todoroki, Koichi Nakamura, Hiroki Kaneko, Koji M. Nishiguchi   +8 more
doaj   +1 more source

Causal Association Between Commonly Used Medicines and Diabetes‐Related Eye Diseases: Univariable and Multivariable Mendelian Randomization Study

Journal of Diabetes Research, Volume 2026, Issue 1, 2026.
Background Diabetic patients require long‐term polypharmacy, yet the causal effects of these medications on ocular complications—specifically diabetic retinopathy (DR), diabetic maculopathy (DMac), and glaucoma—remain unclear due to confounding in observational studies.
Yu Wang, Chak Kwong Cheng, Lamusi A., Mingyue Jin, Chang Wang, Riccardo Calafiore   +5 more
wiley   +1 more source

Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan

Scientific Reports, 2023
This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan.
Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Makiko Nakayama, Yuto Watanabe, Akiko Yamamoto, Yu Wakatsuki, Hajime Onoe, Sorako Wakugawa, Nobuhiro Terao, Taiji Hasegawa, Nozomu Hashiya, Moeko Kawai, Ruka Maruko, Kanako Itagaki, Jyunichiro Honjo, Annabelle A. Okada, Ryusaburo Mori, Hideki Koizumi, Tomohiro Iida, Tetsuju Sekiryu   +22 more
doaj   +1 more source

YOSEMITE and RHINE

Ophthalmology Science, 2022
Purpose: Faricimab is a novel anti–angiopoietin-2 and anti–vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities for both VEGF and angiopoietin-2.
Nicole Eter, MD, PhD, Rishi P. Singh, MD, Francis Abreu, PhD, Kemal Asik, PhD, Karen Basu, PhD, Caroline Baumal, MD, Andrew Chang, PhD, Karl G. Csaky, MD, Zdenka Haskova, MD, PhD, Hugh Lin, MD, Carlos Quezada Ruiz, MD, Paisan Ruamviboonsuk, MD, David Silverman, MSc, MRCOphth, Charles C. Wykoff, MD, PhD, Jeffrey R. Willis, MD, PhD   +14 more
doaj   +1 more source